GRAIL专注于多种癌症早期检测;裁员30%

2024-08-14 05:19

After Tuesday's closing bell, GRAIL (NASDAQ:GRAL) said it would focus its resources going forward on its core multi-cancer early detection programs, resulting in a 30% reduction in headcount.
In addition, investment in programs outside its Galleri early cancer detection test will be greatly reduced.
The cost reductions are projected to extend the company's existing cash runway from H2 2026 into 2028. Also, cash burn in 2025 is expected to lower to $325M.
GRAIL also reported its first quarterly financial results as a standalone company following its June spin-off from Illumina ( ILMN).
Revenue in Q2 was $32M, a 43% year-over-year increase. Its gross loss was -$17.9M, while non-GAAP adjusted gross profit was $16M.
The stock is up ~3% in after-hours trading.

More on GRAIL, Inc.